GAIPET
LIVE

Serial Number

79392554

Owner

ARGORNA PHARMACEUTICALS CO., LTD

Attorney

Jonathan M. Rixen

Filing Date

Nov 8, 2023

Add to watchlist:

No watchlists yet
View on USPTO

GAIPET Trademark

Serial Number: 79392554 • Registration: 7665734

GAIPET is a trademark filed by ARGORNA PHARMACEUTICALS CO., LTD on November 8, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

ARGORNA PHARMACEUTICALS CO., LTD (6 trademarks)

2nd and 4th Floor, Building A, 7 Suida Street,

Entity Type: 99

Trademark Details

Filing Date

November 8, 2023

Registration Date

January 28, 2025

Published for Opposition

December 10, 2024

Goods & Services

Scientific development and research services in the field of drugs; vaccine research and development services; scientific research and development of new products for others; scientific research; research of biochemistry; biotechnology research; pharmaceutical drug research; development services in the field of pharmaceutical drugs; medical research service; biomedical research services

Chemical reagents, other than for medical or veterinary purposes; biological preparations for use in industry and science, other than for medical or veterinary purposes; diagnostic preparations for scientific use, other than for medical or veterinary purposes; test paper, chemical; chemical preparations for scientific purposes, other than for medical or veterinary use; biochemicals preparations for scientific use; chemical substances for analyses in laboratories for scientific use, other than for medical or veterinary purposes; reagent paper, other than for medical or veterinary purpose; biological preparations for cell culture, other than for medical or veterinary use; diagnostic reagents and preparations for scientific use except for medical and veterinary use; active chemical ingredients for use in the manufacture of pharmaceuticals for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia

Medicines for human purposes for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; biochemical medicines for the treatment of tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; pharmaceutical preparations for the treatment of tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; chemical reagents for medical and veterinary purposes; biological preparations for medical purposes for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; reagent paper for medical purposes; drugs for medical purposes for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; diagnostic preparations for medical purposes; vaccines

Filing History

CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jun 17, 2026 CORN
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 12, 2025 OPNX
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 5, 2025 FINO
CORRECTION TRANSACTION RECEIVED FROM IB
Aug 29, 2025 CRCV
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 27, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 27, 2025 OPNR
FINAL DISPOSITION NOTICE SENT TO IB
Aug 15, 2025 FICS
FINAL DISPOSITION PROCESSED
Aug 15, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 29, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 28, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 28, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 10, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 10, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 4, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 18, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 17, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 17, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 17, 2024 TROA
REFUSAL PROCESSED BY IB
Aug 11, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 24, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 24, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 28, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jun 27, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 17, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 5, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 1, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 28, 2024 REPR